 Antitubercular Agents
"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2002 | 4 | 1 | 5 | | 2003 | 3 | 0 | 3 | | 2004 | 3 | 1 | 4 | | 2005 | 2 | 1 | 3 | | 2006 | 2 | 2 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 8 | 4 | 12 | | 2012 | 6 | 5 | 11 | | 2013 | 5 | 0 | 5 | | 2014 | 5 | 3 | 8 | | 2015 | 2 | 1 | 3 | | 2016 | 7 | 5 | 12 | | 2017 | 4 | 0 | 4 | | 2018 | 10 | 4 | 14 | | 2019 | 7 | 2 | 9 | | 2020 | 4 | 3 | 7 | | 2021 | 3 | 5 | 8 | | 2022 | 0 | 2 | 2 | | 2023 | 1 | 6 | 7 | | 2024 | 4 | 2 | 6 | | 2025 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, Mirochnick M, Browning R, Wiesner L, George K, Knowles K, De Koker P, Ngocho JS, Fairlie L, Chakhtoura N, Hesseling AC, Decloedt E, Shapiro DE, van Schalkwyk M. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
-
Singh M, Sarhan MO, Damiba NNL, Singh AK, Villabona-Rueda A, Nino-Meza OJ, Chen X, Masias-Leon Y, Ruiz-Gonzalez CE, Ordonez AA, D'Alessio FR, Aboagye EO, Carroll LS, Jain SK. Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun. 2025 Mar 27; 16(1):3003.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Vel?squez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875.
-
Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Vel?squez GE, Williams B, Yim JJ, Savic R, Hesseling A. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 02; 9(2):100-111.
-
Wynn EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ektnitphong V, Bauman AA, Massoudi LM, Voskuil MI, Robertson GT, Moore CM, Walter ND. Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0131024.
-
Shen D, Ayala A, Reves R, Haas M, Khurana R. Tuberculosis infection prevalence and treatment completion among refugees in the United States. Int J Infect Dis. 2025 Feb; 151:107361.
-
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Cele N, Awolade P, Seboletswe P, Khubone L, Olofinsan K, Islam MS, Jordaan A, Warner DF, Singh P. Synthesis,Antidiabetic and Antitubercular Evaluation of Quinoline-pyrazolopyrimidine hybrids and Quinoline-4-Arylamines. ChemistryOpen. 2024 Sep; 13(9):e202400014.
-
Lyons MA, Obregon-Henao A, Ramey ME, Bauman AA, Pauly S, Rossmassler K, Reid J, Karger B, Walter ND, Robertson GT. Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis. Antimicrob Agents Chemother. 2024 05 02; 68(5):e0101023.
-
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb; 21(2):e1004356.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|